Inversago Pharma Inc. has divulged cannabinoid CB1 receptor antagonists reported to be useful for the treatment of cancer, diabetes, fibrosis, hypertension, irritable bowel syndrome, metabolic syndrome, alopecia and Prader-Willi syndrome.

Shanghai Shenshi Wise Technology Co. Ltd. has identified potassium voltage-gated channel subfamily A member 3 (KCNA3) channel blockers reported to be useful for the treatment of inflammatory and immunological disorders.

Artivila Biopharma Co. Ltd. has synthesized macrocyclic compounds acting as cyclin-dependent kinase 9 (CDK9) inhibitors reported to be useful for the treatment of cancer.

Boehringer Ingelheim Pharma GmbH & Co. KG has disclosed dioxane derivatives acting as mGluR4 negative allosteric modulators reported to be useful for the treatment of neurodegeneration, metabolic disease, cancer, psychiatric disorders and neurological disorders.

Cybin Irl Ltd. has described phenethylamine compounds acting as 5-HT2 receptor agonists reported to be useful for the treatment of lung diseases, cardiovascular disorders, inflammatory disorders, psychiatric disorders and neurological disorders.

Neurocrine Biosciences Inc. has divulged G protein-coupled receptor GPR52 modulators reported to be useful for the treatment of schizophrenia, obsessive-compulsive disorder, attention deficit hyperactivity disorder, bipolar disorder, vascular cognitive impairment, and Alzheimer’s, Parkinson’s and Huntington’s diseases, among other neurological disorders.

Acerand Therapeutics (USA) Ltd. has identified fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of cancer.

Mitobridge Inc. has synthesized dynamin-1-like protein (DNM1L; DRP1) inhibitors reported to be useful for the treatment of cancer, acute kidney injury, metabolic diseases and more.

Astellas Pharma Inc. and Kotobuki Pharmaceutical Co. Ltd. have disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of neurodegeneration and inflammatory disorders.